A Prospective, Multi-center Study of Newly Diagnosed Marginal Zone B-cell Lymphoma Observing Treatment Results and Disease Outcomes

What this Trial Is About

Marginal zone lymphoma MZL is a type of lymphoma that can develop in the spleen, lymph nodes, and mucosal lymphoid tissues, with its occurrence increasing with age. This research aims to describe the clinical features, diagnosis, treatment status, disease progression, and main outcomes of various MZL subtypes, including mucosa-associated lymphoid tissue MALT lymphoma, spleen MZL, lymph node MZL, primary cutaneous MZL, and pediatric NMZL. The study also observes the safety and effectiveness of different treatments currently used for these subtypes. Participants diagnosed with MZL within the past 6 months and who have not received prior anti-tumor therapy will be enrolled. They will receive the best available treatment or follow-up based on their disease characteristics, as determined by their healthcare provider. The study does not specify a fixed treatment plan but follows patients over time to monitor their response and progression. During the study, researchers will collect medical histories, biological samples such as blood and tumor tissue, and oncology data. They will track progression-free survival for up to 10 years and assess other outcomes like time to treatment, overall survival, adverse events, and rates of disease transformation or second tumors. Participants will be followed long-term with regular evaluations to understand their disease course and treatment effects.

A Cohort Study in Newly Diagnosed MZL